150 related articles for article (PubMed ID: 16212670)
1. Modeling the effect of age in T1-2 breast cancer using the SEER database.
Tai P; Cserni G; Van De Steene J; Vlastos G; Voordeckers M; Royce M; Lee SJ; Vinh-Hung V; Storme G
BMC Cancer; 2005 Oct; 5():130. PubMed ID: 16212670
[TBL] [Abstract][Full Text] [Related]
2. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
Liu YR; Jiang YZ; Yu KD; Shao ZM
Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
[TBL] [Abstract][Full Text] [Related]
3. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older.
Yancik R; Wesley MN; Ries LA; Havlik RJ; Edwards BK; Yates JW
JAMA; 2001 Feb; 285(7):885-92. PubMed ID: 11180731
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016.
Thomas A; Rhoads A; Suhl J; Conway KM; Hundley WG; McNally LR; Oleson J; Melin SA; Lynch CF; Romitti PA
Clin Breast Cancer; 2020 Aug; 20(4):e410-e422. PubMed ID: 32278642
[TBL] [Abstract][Full Text] [Related]
5. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database.
Chen HL; Zhou MQ; Tian W; Meng KX; He HF
PLoS One; 2016; 11(10):e0165409. PubMed ID: 27798652
[TBL] [Abstract][Full Text] [Related]
6. A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010.
Munoz DF; Xu C; Plevritis SK
Med Decis Making; 2018 Apr; 38(1_suppl):89S-98S. PubMed ID: 29554473
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.
Elkin EB; Hurria A; Mitra N; Schrag D; Panageas KS
J Clin Oncol; 2006 Jun; 24(18):2757-64. PubMed ID: 16782916
[TBL] [Abstract][Full Text] [Related]
8. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer survival in African-American women by hormone receptor subtypes.
Akinyemiju T; Moore JX; Altekruse SF
Breast Cancer Res Treat; 2015 Aug; 153(1):211-8. PubMed ID: 26250393
[TBL] [Abstract][Full Text] [Related]
10. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome.
Anderson WF; Jatoi I; Devesa SS
Breast Cancer Res Treat; 2005 Mar; 90(2):127-37. PubMed ID: 15803359
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
[TBL] [Abstract][Full Text] [Related]
12. Older Patients With Early-stage Breast Cancer: Adjuvant Radiation Therapy and Predictive Factors for Cancer-related Death.
Nagar H; Yan W; Christos P; Chao KSC; Nori D; Ravi A
Am J Clin Oncol; 2017 Jun; 40(3):300-305. PubMed ID: 25333731
[TBL] [Abstract][Full Text] [Related]
13. Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study.
Yu P; Tang H; Zou Y; Liu P; Tian W; Zhang K; Xie X; Ye F
Cancer Control; 2020; 27(1):1073274820976667. PubMed ID: 33356518
[TBL] [Abstract][Full Text] [Related]
14. A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis.
Giannakeas V; Sopik V; Narod SA
Breast Cancer Res Treat; 2018 Jun; 169(3):587-594. PubMed ID: 29445939
[TBL] [Abstract][Full Text] [Related]
15. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
Dunnwald LK; Rossing MA; Li CI
Breast Cancer Res; 2007; 9(1):R6. PubMed ID: 17239243
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
Narod SA; Iqbal J; Giannakeas V; Sopik V; Sun P
JAMA Oncol; 2015 Oct; 1(7):888-96. PubMed ID: 26291673
[TBL] [Abstract][Full Text] [Related]
17. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
18. Real-world impact of non-breast cancer-specific death on overall survival in resectable breast cancer.
Fu J; Wu L; Jiang M; Li D; Jiang T; Fu W; Wang L; Du J
Cancer; 2017 Jul; 123(13):2432-2443. PubMed ID: 28267199
[TBL] [Abstract][Full Text] [Related]
19. How Young Is Too Young in Breast Cancer?-Young Breast Cancer Is Not a Unique Biological Subtype.
Fu J; Wu L; Fu W; Tan Y; Xu T; Hong Z; Wang F; Li S
Clin Breast Cancer; 2018 Feb; 18(1):e25-e39. PubMed ID: 28802528
[TBL] [Abstract][Full Text] [Related]
20. Cause-specific mortality among patients with different molecular subtypes of T1-2N0M0 breast cancer: A population-based study.
Wang D; Yi L; Zhang L; Wang Z
Medicine (Baltimore); 2021 Oct; 100(43):e27605. PubMed ID: 34713838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
